{"ticker": {"uuid": "dc546a45-587a-47b8-a7e0-ece1ab56c98e", "symbol": "GPCR", "name": "Structure Therapeutics Inc. American Depositary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Structure Therapeutics (NASDAQ: GPCR) CSO exercises options and sells ADS", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQa3QtbFpmU3Y3T0Q5WlVJYndIbXFCUTlWQWl3U1ROTGt6VW5lejdnYnhVNnRMRHAwMGdiX2ZHYjNncUx6MUwxanNSaGgwOTNBR0Foc3RfakRwMmh5ak9qWHBwb2kyeV9oVmRKM3VDaTJ3WG5RazJXT2JoUVhwVTNrWjZBQUxSbURhUGw4QUx0UWhFM0xUNlM3dVFnX0VpVUs2RnZvTWliOXYzZDI5T3JMY0FaTks2M1NGVVI1dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T22:58:21+00:00", "published_display": "15 Jul 2026 22:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Structure Therapeutics (GPCR) Is Up 7.5% After Strong Oral GLP-1 Phase 2b Data And Insider Sale - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPdXdnWnJySVF3SW9VcUpYd255ZC1VSF96cGhpS1FpVkk2b2JhSzdpYkpJUTRvZjFIbS0tNVc0TkUxMG5MS1JaVzVsRTdERTRCRjdSTHg1VExOZG1HMG1rYWRoanhLTWF4dFllTjJiY2lWZTdiM1hSaHpGeDRZd0JJQjl6cHJlSUFpMU15cFc4c2xHRXplSmptck53alNlS3RjeHRTaTFR?oc=5", "source_name": "Market source", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Structure Therapeutics Inc. Insider Trading Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPeUVnZFltUHY2d0tBb0FHazZ4S2UxbGZwSk5WMHdjNkZUOHBNT3htV1JValZTQnJIZTZ2NGc0X1pMV3RRN2dkWEV0V3BHSDE0Y0JKZUo3QjBRRFM0OHdJelZlSEV6VVUxYkQ0Ukswd0RzSFcwQTJMeS15U0dRWDk3Wm9CVXA4UGw4M09KOGN3Z0dGTVRaRjRKT0VVTTc2Tmp2cFpzZ1Q3TzlZLUs5a0hMUW1rckhFR3dMNmtNbA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics (GPCR) director receives 39,453 share options at $15", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQVVU5d3paVXhRNjZFeTcyRGNMOFltcy1VWjBrRzE5dUJDb2dhbjJVSFlEaFVXUkE0bDhnMEttQm9MZnBBbktNUVZQM09nSG9ZMkRtcHo4WkRrMl8tZ1RYMVZGYm5CakVNTmhaUG9vQmJjZUtEdHZzSzNXblJLeDdPdkNwMjRCdHVENGp0NjBzaEFEYkdYSGtXcDhyb2w5RnIzMU9GU2hHU2FjdU1nTlNscGJibkJmdVMtNEpDaA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPMVpsNkpCMm9SeEQwTzFRQVB1a1pRSWU0enFXLVNTcnRTS1NwY2h1eEVQb2RaYVdITndYSVFVQkM0d0JHVGt4NFR1NHlERTJ0ZEI1VVBhdFl2REplaHE3U2FNZ0NnT1hKTVhJaXZDdGJnUXQ1bWlQbmlLSlFfSlZYb3pBcEhzbWkxaXViSDdmaGpkN0Rk?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics (GPCR) Stock After Phase 2b Obesity Data What Does A 2x P/B Multiple Suggest?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade) (GPCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQaUpMa1VOZXZFZUlvaU9xaExUeHBsSVhheXFZOC1UeTU4MVZpMjFDdS16OWNRekloQ25VNUQ3UTF6SHBwX1hLdk9fbWlaNnFVLVlyRjA1aUxybktpN1dFaG14TmhOZTc3THprU1M1RjRjcnVKdTREX1ZncHZMckhWVFhBSXBKbDd3X1UweWhGR2x6ZmljdWhTelJPd2U0aktIN1FmcTlmWUVjRWJSOTQycWlxRXlfdlk?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Phase 2b Oral GLP-1 Data on Aleniglipron Change The Bull Case For Structure Therapeutics (GPCR)?", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/does-phase-2b-oral-glp-131837224.html", "source_name": "Simply Wall St.", "published_at": "2026-06-07T13:18:37+00:00", "published_display": "07 Jun 2026 13:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOZlYtVHMyYjktT0tTeVVpaWNuMzJxWEs2aVB0MGp2TzdrVHVxQWpxVE0wUmRsY3BWZTRNeDNTendSTmFib2FJSDYwNjBrQTZ3MzVHMTNycWFYNFZsdWc5TnVISEpyZzg0N2RfS0lTenYxUmdITmZ2bnkwYUxYaDhmNUlGWGJtQlNmNEUzMHZBMk1hZmtZT1JyU0s5UktFbXZWdWVvX0VZNzlkZmZSS3ZDdzRQOA?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/structure-therapeutics-announces-publication-nature-200500995.html", "source_name": "GlobeNewswire", "published_at": "2026-06-05T20:05:00+00:00", "published_display": "05 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GPCR Stock Price and Chart \u2014 NASDAQ:GPCR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE81a1NWeEl5aUdybGtlbnM1cWVCYUNmbGxqNldfV1Y2TTUyTnFBUFA1VGdBaWFldkJkbExNb3AyX3U3bjRwR2JSVEtvdExBNndVbW1yLXU0TUhBeGVV?oc=5", "source_name": "TradingView", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics Announces Participation in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/structure-therapeutics-announces-participation-upcoming-200500356.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T20:05:00+00:00", "published_display": "26 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If Viking Therapeutics Is Acquired, Here\u2019s Who Wins", "summary": "", "url": "https://finance.yahoo.com/m/9e744f99-48a9-35c4-9aa2-72ffa90f3ebd/if-viking-therapeutics-is.html", "source_name": "24/7 Wall St.", "published_at": "2026-05-26T12:50:16+00:00", "published_display": "26 May 2026 12:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hear Structure Therapeutics at Jefferies and Goldman Sachs healthcare talks", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQNE9jbmVHdE9MazQ0ZnRqcTF4TkVuXy15RkF4ZHRCZUlMcUVockpaZ3IxbXhaSHA3N25oRVd2em0yZnlyQ2ljXzRYVU5KVFAwNGVVLVJpWGFJbllud25xYmVha3J6cVdxR0oyT2M4cHdOWXNqTFhGS0FNdlR4ZGNiN1dtX1FuNW85ekh5TENDb0tiTENhU1ZGRjhVdEtDN0tqYUNVYlNjZTBtOWRiZ2lYY0ZXUEhZdHhud2JRZWtPMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNVWJocXhTbWZpdDFiMVJXeGRhcXp1S2Y1S1dEaTRkSEZTTkxsX1RlZ3gtX0tRelJFZ29JYTlWRUh3Q0lXLUNPNWVkUmFfMnk0UkRHaFFnekszVlFHME5qYmIxZV9WOXZVZXg5QnVMR0N0NUp4dUJYaEU0REZXVlo3SGF5eGhrcGtFOXQ5b0d5TEJKMVQ0TTF6elBTdUx5SlZGSXc?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Structure Therapeutics (GPCR) Is Down 7.2% After Strong Oral GLP-1 Phase 2 Data And FDA Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNV2g3d0JaWDdLTXl1eG5pRjJ5TXpYVEc3RndReFV0R3pTMW0wU2FrV0RRQ09OZXp0QThYNTNGZGVnck1oZ08yV29nZGFWbEttcktQa2NNaXllWmFYZXNOMFdGTWp4SFB1VFZCMFQ3QTFieUNiQ01iN3VxeERxVUJrbkwzVTVXZFVxN0IzelRGWmdtczBzQWJ0TUFOSUZTcFptZTFLX29LY0s?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQbVgtblh3TW9lZUxyQ2JVaVhzaXExN3hFNTNzRmlzd0xQWkRHZXliUFc0TEpVVGhqLUhqbll0UEQ5YjcwY01HcENyNVhKTktKZlRYaFlyUUhOTHlNSkxVQXh3STZwUktYalVoeFVkbjlUc3I3UDJzYUV3dW9XYjNtMFJSeFlQTFo5NGZVeGJqMzF4QVZvXzFWUXBUeHg0YjNXWnBLZy1BRQ?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Metsera legal chief joins Structure as COO ahead of Phase 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNVnhfZEJMSWNQYjhqRUdtSjA0YXFybUI3dldCUTBVLXVKdzBRQ3NoS2ROQ0sxVUpWVVluVUtLOWp1bzA0YXJRcVZqY2Jwb3FYWGlrWldCd3I2R3lDWDlhQ2VITUtiblVXTF9oS2NPa3hjUmtMMmZqQl9UUGtZYjJkSFhZY3ctS1B5V3lFb2QyRXNyVnhxTzhfZ0FfTkx6SWZCeFNTRTdoeUVzT3VhRFhYbTRJWHZaNzFoVjN2UkJ6TQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Structure Therapeutics (GPCR) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPUTJwMk1OOFBOYkJlTEhqMHpBV0U1c0NoVGV1M2Z0QU4yTWwyM0ZSNnd3SDM4SmVPOF9qLWdINDZGbHNOXzl5R0x1M2ZHVTAydGVvaFhpeGQ2bWdpenR5SVp5VXVOSkdoVWsyM3pWNGdQMjU3TjlVaEl3UFhmLVN1NkNqb0V6TFRXZ2xLV3FaYXhpOGlHQjA2NGJPX2dPYWpjTlJTN3BZVFRHRGkzUm8zQjBn?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 Blockbuster (GPCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQVzJuV1prUnFyMnJYWnFQN3pUbERSdDNaTFlDbktaOWEyejE2bmZydnpDeW84NzNCdVpfYVgzRXhhOFJnbVcyVTJEU29YcWVQLTI4X1F1WVh0QTBMQ2FpdG05VTE0ZXFBSmtTeUtPWlNvUnJTRGFSaDU2VHZSNThtMmJJRV9Va2hfZV9QTXdsLVRFNjEzMWV4SGo2dEsxbWlpSHFoOXBSNDh0TmF4amM0ellySFBmNWdQbEZYVEc4Q3JLMmc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPYzQ2VHhxdUpGWHFLRUdpMHUxMjVhUTVuNTJTSnY5WHJDekZCNmczRm5GMjJrR01rRVplSzA2LVpoV1pBQ2NDQkVLWlRNazFuNlFvVEhNUklUazRkTFBzRTJnVTBNUTFYV0hTT3dmc1pWaDJRYU1tMzc4SlJVTUFYNk5CUmg2REc2ZE1mLQ?oc=5", "source_name": "Market source", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Structure Therapeutics (NASDAQ: GPCR) CSO exercises options and sells ADS", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQa3QtbFpmU3Y3T0Q5WlVJYndIbXFCUTlWQWl3U1ROTGt6VW5lejdnYnhVNnRMRHAwMGdiX2ZHYjNncUx6MUwxanNSaGgwOTNBR0Foc3RfakRwMmh5ak9qWHBwb2kyeV9oVmRKM3VDaTJ3WG5RazJXT2JoUVhwVTNrWjZBQUxSbURhUGw4QUx0UWhFM0xUNlM3dVFnX0VpVUs2RnZvTWliOXYzZDI5T3JMY0FaTks2M1NGVVI1dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T22:58:21+00:00", "published_display": "15 Jul 2026 22:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics (GPCR) Is Up 7.5% After Strong Oral GLP-1 Phase 2b Data And Insider Sale - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPdXdnWnJySVF3SW9VcUpYd255ZC1VSF96cGhpS1FpVkk2b2JhSzdpYkpJUTRvZjFIbS0tNVc0TkUxMG5MS1JaVzVsRTdERTRCRjdSTHg1VExOZG1HMG1rYWRoanhLTWF4dFllTjJiY2lWZTdiM1hSaHpGeDRZd0JJQjl6cHJlSUFpMU15cFc4c2xHRXplSmptck53alNlS3RjeHRTaTFR?oc=5", "source_name": "Market source", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Structure Therapeutics Inc. Insider Trading Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPeUVnZFltUHY2d0tBb0FHazZ4S2UxbGZwSk5WMHdjNkZUOHBNT3htV1JValZTQnJIZTZ2NGc0X1pMV3RRN2dkWEV0V3BHSDE0Y0JKZUo3QjBRRFM0OHdJelZlSEV6VVUxYkQ0Ukswd0RzSFcwQTJMeS15U0dRWDk3Wm9CVXA4UGw4M09KOGN3Z0dGTVRaRjRKT0VVTTc2Tmp2cFpzZ1Q3TzlZLUs5a0hMUW1rckhFR3dMNmtNbA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics (GPCR) director receives 39,453 share options at $15", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQVVU5d3paVXhRNjZFeTcyRGNMOFltcy1VWjBrRzE5dUJDb2dhbjJVSFlEaFVXUkE0bDhnMEttQm9MZnBBbktNUVZQM09nSG9ZMkRtcHo4WkRrMl8tZ1RYMVZGYm5CakVNTmhaUG9vQmJjZUtEdHZzSzNXblJLeDdPdkNwMjRCdHVENGp0NjBzaEFEYkdYSGtXcDhyb2w5RnIzMU9GU2hHU2FjdU1nTlNscGJibkJmdVMtNEpDaA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPMVpsNkpCMm9SeEQwTzFRQVB1a1pRSWU0enFXLVNTcnRTS1NwY2h1eEVQb2RaYVdITndYSVFVQkM0d0JHVGt4NFR1NHlERTJ0ZEI1VVBhdFl2REplaHE3U2FNZ0NnT1hKTVhJaXZDdGJnUXQ1bWlQbmlLSlFfSlZYb3pBcEhzbWkxaXViSDdmaGpkN0Rk?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics (GPCR) Stock After Phase 2b Obesity Data What Does A 2x P/B Multiple Suggest?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade) (GPCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQaUpMa1VOZXZFZUlvaU9xaExUeHBsSVhheXFZOC1UeTU4MVZpMjFDdS16OWNRekloQ25VNUQ3UTF6SHBwX1hLdk9fbWlaNnFVLVlyRjA1aUxybktpN1dFaG14TmhOZTc3THprU1M1RjRjcnVKdTREX1ZncHZMckhWVFhBSXBKbDd3X1UweWhGR2x6ZmljdWhTelJPd2U0aktIN1FmcTlmWUVjRWJSOTQycWlxRXlfdlk?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Phase 2b Oral GLP-1 Data on Aleniglipron Change The Bull Case For Structure Therapeutics (GPCR)?", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/does-phase-2b-oral-glp-131837224.html", "source_name": "Simply Wall St.", "published_at": "2026-06-07T13:18:37+00:00", "published_display": "07 Jun 2026 13:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOZlYtVHMyYjktT0tTeVVpaWNuMzJxWEs2aVB0MGp2TzdrVHVxQWpxVE0wUmRsY3BWZTRNeDNTendSTmFib2FJSDYwNjBrQTZ3MzVHMTNycWFYNFZsdWc5TnVISEpyZzg0N2RfS0lTenYxUmdITmZ2bnkwYUxYaDhmNUlGWGJtQlNmNEUzMHZBMk1hZmtZT1JyU0s5UktFbXZWdWVvX0VZNzlkZmZSS3ZDdzRQOA?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/structure-therapeutics-announces-publication-nature-200500995.html", "source_name": "GlobeNewswire", "published_at": "2026-06-05T20:05:00+00:00", "published_display": "05 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GPCR Stock Price and Chart \u2014 NASDAQ:GPCR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE81a1NWeEl5aUdybGtlbnM1cWVCYUNmbGxqNldfV1Y2TTUyTnFBUFA1VGdBaWFldkJkbExNb3AyX3U3bjRwR2JSVEtvdExBNndVbW1yLXU0TUhBeGVV?oc=5", "source_name": "TradingView", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics Announces Participation in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/structure-therapeutics-announces-participation-upcoming-200500356.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T20:05:00+00:00", "published_display": "26 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If Viking Therapeutics Is Acquired, Here\u2019s Who Wins", "summary": "", "url": "https://finance.yahoo.com/m/9e744f99-48a9-35c4-9aa2-72ffa90f3ebd/if-viking-therapeutics-is.html", "source_name": "24/7 Wall St.", "published_at": "2026-05-26T12:50:16+00:00", "published_display": "26 May 2026 12:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hear Structure Therapeutics at Jefferies and Goldman Sachs healthcare talks", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQNE9jbmVHdE9MazQ0ZnRqcTF4TkVuXy15RkF4ZHRCZUlMcUVockpaZ3IxbXhaSHA3N25oRVd2em0yZnlyQ2ljXzRYVU5KVFAwNGVVLVJpWGFJbllud25xYmVha3J6cVdxR0oyT2M4cHdOWXNqTFhGS0FNdlR4ZGNiN1dtX1FuNW85ekh5TENDb0tiTENhU1ZGRjhVdEtDN0tqYUNVYlNjZTBtOWRiZ2lYY0ZXUEhZdHhud2JRZWtPMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNVWJocXhTbWZpdDFiMVJXeGRhcXp1S2Y1S1dEaTRkSEZTTkxsX1RlZ3gtX0tRelJFZ29JYTlWRUh3Q0lXLUNPNWVkUmFfMnk0UkRHaFFnekszVlFHME5qYmIxZV9WOXZVZXg5QnVMR0N0NUp4dUJYaEU0REZXVlo3SGF5eGhrcGtFOXQ5b0d5TEJKMVQ0TTF6elBTdUx5SlZGSXc?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Structure Therapeutics (GPCR) Is Down 7.2% After Strong Oral GLP-1 Phase 2 Data And FDA Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNV2g3d0JaWDdLTXl1eG5pRjJ5TXpYVEc3RndReFV0R3pTMW0wU2FrV0RRQ09OZXp0QThYNTNGZGVnck1oZ08yV29nZGFWbEttcktQa2NNaXllWmFYZXNOMFdGTWp4SFB1VFZCMFQ3QTFieUNiQ01iN3VxeERxVUJrbkwzVTVXZFVxN0IzelRGWmdtczBzQWJ0TUFOSUZTcFptZTFLX29LY0s?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQbVgtblh3TW9lZUxyQ2JVaVhzaXExN3hFNTNzRmlzd0xQWkRHZXliUFc0TEpVVGhqLUhqbll0UEQ5YjcwY01HcENyNVhKTktKZlRYaFlyUUhOTHlNSkxVQXh3STZwUktYalVoeFVkbjlUc3I3UDJzYUV3dW9XYjNtMFJSeFlQTFo5NGZVeGJqMzF4QVZvXzFWUXBUeHg0YjNXWnBLZy1BRQ?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metsera legal chief joins Structure as COO ahead of Phase 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNVnhfZEJMSWNQYjhqRUdtSjA0YXFybUI3dldCUTBVLXVKdzBRQ3NoS2ROQ0sxVUpWVVluVUtLOWp1bzA0YXJRcVZqY2Jwb3FYWGlrWldCd3I2R3lDWDlhQ2VITUtiblVXTF9oS2NPa3hjUmtMMmZqQl9UUGtZYjJkSFhZY3ctS1B5V3lFb2QyRXNyVnhxTzhfZ0FfTkx6SWZCeFNTRTdoeUVzT3VhRFhYbTRJWHZaNzFoVjN2UkJ6TQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Structure Therapeutics (GPCR) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPUTJwMk1OOFBOYkJlTEhqMHpBV0U1c0NoVGV1M2Z0QU4yTWwyM0ZSNnd3SDM4SmVPOF9qLWdINDZGbHNOXzl5R0x1M2ZHVTAydGVvaFhpeGQ2bWdpenR5SVp5VXVOSkdoVWsyM3pWNGdQMjU3TjlVaEl3UFhmLVN1NkNqb0V6TFRXZ2xLV3FaYXhpOGlHQjA2NGJPX2dPYWpjTlJTN3BZVFRHRGkzUm8zQjBn?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 Blockbuster (GPCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQVzJuV1prUnFyMnJYWnFQN3pUbERSdDNaTFlDbktaOWEyejE2bmZydnpDeW84NzNCdVpfYVgzRXhhOFJnbVcyVTJEU29YcWVQLTI4X1F1WVh0QTBMQ2FpdG05VTE0ZXFBSmtTeUtPWlNvUnJTRGFSaDU2VHZSNThtMmJJRV9Va2hfZV9QTXdsLVRFNjEzMWV4SGo2dEsxbWlpSHFoOXBSNDh0TmF4amM0ellySFBmNWdQbEZYVEc4Q3JLMmc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPYzQ2VHhxdUpGWHFLRUdpMHUxMjVhUTVuNTJTSnY5WHJDekZCNmczRm5GMjJrR01rRVplSzA2LVpoV1pBQ2NDQkVLWlRNazFuNlFvVEhNUklUazRkTFBzRTJnVTBNUTFYV0hTT3dmc1pWaDJRYU1tMzc4SlJVTUFYNk5CUmg2REc2ZE1mLQ?oc=5", "source_name": "Market source", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 79, "total_relevant": 30, "sentiment_summary": {"positive": 6, "negative": 1, "neutral": 23, "score": 53, "total": 30, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 11.35, "count": 20}, {"event": "earnings", "label": "Earnings", "weight": 3.3, "count": 8}, {"event": "analyst", "label": "Analyst action", "weight": 1.45, "count": 2}], "positive_events": 6, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 53.36, "latest_week": "2026-07-10", "one_week_move": -0.2, "four_week_move": 24.3, "twelve_week_move": 5.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.159782, "market_dynamics_buy_signal": false, "relative_strength": 3.615965, "fair_value_gap": 36.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 38.301, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.2% over one week, +24.3% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 53, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "Stock Titan", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "Seeking Alpha", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "Simply Wall St.", "count": 1}, {"label": "TradingView", "count": 1}, {"label": "24/7 Wall St.", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 22}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 20}, {"label": "Earnings", "count": 8}, {"label": "Analyst action", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "22", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.2% over one week, +24.3% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Structure Therapeutics (NASDAQ: GPCR) CSO exercises options and sells ADS"}], "updated_at": "2026-07-18T08:17:23.312318+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}